Unibest
← Back to patent-cliff list

CAS 3282-30-2

pivaloyl chloride

Codes: DAPA-013, EFAV-002, PRUC-002, IXAB-079, PEME-002, SIVE-009

Application context (from source-drug indications)

Type 2 diabetesDapagliflozin Propanediol/Metformin HydrochlorideHIV infectionEfavirenz/Lamivudine/Tenofovir Disoproxil FumarateConstipationPrucalopride SuccinatePostoperative complicationPrucalopride SuccinateEnteral feeding intolerancePrucalopride SuccinateOpioid-induced constipationPrucalopride SuccinatePainPrucalopride SuccinateIntestinal pseudo-obstructionPrucalopride SuccinateBreast cancerIxabepiloneMetastatic breast cancerIxabepiloneCervical cancerIxabepiloneProstate cancerIxabepiloneSolid tumourIxabepiloneNeutropeniaIxabepiloneChronic renal impairmentDapagliflozin Propanediol MonohydrateHeart failureDapagliflozin Propanediol MonohydrateKidney diseaseDapagliflozin Propanediol MonohydrateType 1 diabetesDapagliflozin Propanediol MonohydrateType 2 diabetesDapagliflozin Propanediol MonohydratePolycystic ovary syndromeDapagliflozin Propanediol MonohydrateHIV infectionEfavirenzCreutzfeldt-Jakob diseaseEfavirenzAlzheimer's diseaseEfavirenzPancreatic cancerEfavirenzProstate cancerEfavirenzNon-Hodgkin lymphomaEfavirenzNon-small cell lung cancerPemetrexed Disodium Hydrate间皮组织肿瘤Pemetrexed Disodium Hydrate胸膜孤立性纤维瘤Pemetrexed Disodium HydrateBladder cancerPemetrexed Disodium HydrateUrothelial carcinomaPemetrexed Disodium HydrateSolid tumourPemetrexed Disodium HydrateAcute lung injurySivelestat Sodium Hydrate全身炎症反应综合征Sivelestat Sodium Hydrate视神经脊髓炎Sivelestat Sodium Hydrate感染性休克Sivelestat Sodium Hydrate血液凝固障碍Sivelestat Sodium HydrateCoronary artery lesionSivelestat Sodium Hydrate

Source drugs (routes using this intermediate)

DrugTierExpiry
Dapagliflozin Propanediol/Metformin HydrochlorideTier A — Act now2030
Efavirenz/Lamivudine/Tenofovir Disoproxil FumarateTier C — Watch / trade-
Prucalopride SuccinateTier C — Watch / trade-
IxabepiloneTier C — Watch / trade-
Dapagliflozin Propanediol MonohydrateTier B — Position early-
EfavirenzTier B — Position early-
Pemetrexed Disodium HydrateTier B — Position early-
Sivelestat Sodium HydrateTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

IxabepiloneOptimised routesteps: 16total yield: 18 mg
(4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→4-((S,1E,5Z)-3-azido-6-iodo-2-methylhepta-1,5-dien-1-yl)-2-methylthiazole→(S)-2-hydroxysuccinic acid→(S)-2-(3-oxo-1,4-dioxaspiro[4.5]decan-2-yl)acetic acid→(S)-3-hydroxydihydrofuran-2(3H)-one→(S)-3-((tert-butyldimethylsilyl)oxy)dihydrofuran-2(3H)-one→(S)-3,5-bis((tert-butyldimethylsilyl)oxy)pentan-2-one→diethyl ((2-methylthiazol-4-yl)methyl)phosphonate→(S,E)-4-(3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylpent-1-en-1-yl)-2-methylthiazole→(S,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-5-(2-methylthiazol-4-yl)pent-4-en-1-ol→(S,E)-3-((tert-butyldimethylsilyl)oxy)-4-methyl-5-(2-methylthiazol-4-yl)pent-4-enal→4-((S,1E,5Z)-3-((tert-butyldimethylsilyl)oxy)-6-iodo-2-methylhepta-1,5-dien-1-yl)-2-methylthiazole→(S,1E,5Z)-6-iodo-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-ol→tert-butyl (3R,6R,7S,8S)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8-tetramethyl-5-oxoundec-10-enoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-azido-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-((tert-butoxycarbonyl)amino)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→tert-butyl (6R,7S,8S,12Z,15S,16E)-15-((tert-butoxycarbonyl)amino)-7-((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-3,5-dioxoheptadeca-12,16-dienoate→tert-butyl (3S,6R,7S,8S,12Z,15S,16E)-15-amino-7-((tert-butyldimethylsilyl)oxy)-3-hydroxy-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoate→4-(chloromethyl)-2-methylthiazole hydrochloride→5-(benzyloxy)pentanal→pivaloyl chloride→(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol→5-(benzyloxy)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylpentanamide→(S)-5-(benzyloxy)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N,2-dimethylpentanamide→(S)-5-(benzyloxy)-2-methylpentan-1-ol→(S)-5-(benzyloxy)-2-methylpentanal→(S)-4-benzyl-3-propionyloxazolidin-2-one→(R)-4-benzyl-3-((2R,3S,4S)-7-(benzyloxy)-3-hydroxy-2,4-dimethylheptanoyl)oxazolidin-2-one→N,O-dimethylhydroxylamine hydrochloride→(2R,3S,4S)-7-(benzyloxy)-3-hydroxy-N-methoxy-N,2,4-trimethylheptanamide→(2R,3S,4S)-7-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-N-methoxy-N,2,4-trimethylheptanamide→(2R,3S,4S)-7-(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-2,4-dimethylheptanal→(2-methylbut-3-en-2-yl)magnesium chloride→(5R,6S,7S)-10-(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)-3,3,5,7-tetramethyldec-1-en-4-one→(4R,5S,6S)-9-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-2,2,4,6-tetramethyl-3-oxononanal→tert-butyl (3R,6R,7S,8S)-11-(benzyloxy)-7-((tert-butyldimethylsilyl)oxy)-3-hydroxy-4,4,6,8-tetramethyl-5-oxoundecanoate→tert-butyl (3R,6R,7S,8S)-11-(benzyloxy)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8-tetramethyl-5-oxoundecanoate→tert-butyl (3R,6R,7S,8S)-3,7-bis((tert-butyldimethylsilyl)oxy)-11-hydroxy-4,4,6,8-tetramethyl-5-oxoundecanoate

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.